192 related articles for article (PubMed ID: 19015070)
1. Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.
García-Mata J; García-Palomo A; Calvo L; Mel R; Cruz JJ; Ramos M
Clin Transl Oncol; 2008 Nov; 10(11):739-44. PubMed ID: 19015070
[TBL] [Abstract][Full Text] [Related]
2. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
Antolín S; Mel R; Ramos M; García-Palomo A; Almanza C; de Paz L; Calvo L; Alvarez E; González A; García-Mata J
Clin Transl Oncol; 2011 Sep; 13(9):686-91. PubMed ID: 21865141
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.
Malhotra V; Dorr VJ; Lyss AP; Anderson CM; Westgate S; Reynolds M; Barrett B; Perry MC
Clin Breast Cancer; 2004 Dec; 5(5):377-84. PubMed ID: 15585077
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
[TBL] [Abstract][Full Text] [Related]
7. [Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin].
Liutkauskiene S; Sveikata A; Juozaityte E; Characiejus D; Juodzbaliene E; Kregzdyte R; Fokas V
Medicina (Kaunas); 2009; 45(8):600-6. PubMed ID: 19773618
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
[TBL] [Abstract][Full Text] [Related]
12. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
[TBL] [Abstract][Full Text] [Related]
13. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
[TBL] [Abstract][Full Text] [Related]
15. Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
Al-Tweigeri TA; Ajarim DS; Alsayed AA; Rahal MM; Alshabanah MO; Tulbah AM; Al-Malik OA; Fatani DM; El-Husseiny GA; Elkum NB; Ezzat AA
Med Oncol; 2010 Sep; 27(3):571-7. PubMed ID: 19526202
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.
von Minckwitz G; Costa SD; Raab G; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Gademann G; Tulusan AH; Eiermann W; Graf E; Kaufmann M;
J Clin Oncol; 2001 Aug; 19(15):3506-15. PubMed ID: 11481357
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
19. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]